Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
156.90
-0.79 (-0.50%)
At close: Jul 11, 2025, 4:00 PM
156.87
-0.03 (-0.02%)
After-hours: Jul 11, 2025, 7:48 PM EDT
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
$646,857
Profits / Employee
$157,929
Market Cap
377.51B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
JNJ News
- 1 day ago - Mar Vista U.S. Quality Q2 2025 Top Contributors And Detractors - Seeking Alpha
- 2 days ago - Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
- 2 days ago - 3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies - Seeking Alpha
- 3 days ago - Johnson & Johnson's Outlook Clouded By $2 Billion Headwind - Benzinga
- 3 days ago - Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings? - Seeking Alpha
- 4 days ago - Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon' - CNBC
- 4 days ago - Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others - CNBC
- 4 days ago - Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo - PRNewsWire